You just read:

SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)

News provided by

SCYNEXIS, Inc.

May 06, 2019, 08:30 ET